Rani Therapeutics (RANI) - 2024 Q1 - Quarterly Results

First Quarter 2024 and Subsequent Highlights: Exhibit 99.1 Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 – - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 - SAN JOSE, Calif., May 6, 2024 --Rani Therapeutics Holding ...